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Abstract
Background: The prevalence of anemia in the intensive care unit is well-described. Less is known, however, of the
prevalence of anemia in hospitalized patients with lesser illness severity or without organ dysfunction. Community-
acquired pneumonia (CAP) is one of the most frequent reasons for hospitalization in the United States (US),
affecting both healthy patients and those with comorbid illness, and is typically not associated with acute blood
loss. Our objective was to examine the development and progression of anemia and its association with 90d
mortality in 1893 subjects with CAP presenting to the emergency departments of 28 US academic and community
hospitals.
Methods: We utilized hemoglobin values obtained for clinical purposes, classifying subjects into categories
consisting of no anemia (hemoglobin >13 g/dL), at least borderline (≤ 13 g/dL), at least mild (≤ 12 g/dL), at least
moderate (≤ 10 g/dL), and severe (≤ 8 g/dL) anemia. We stratified our results by gender, comorbidity, ICU
admission, and development of severe sepsis. We used multivariable logistic regression to determine factors
independently associated with the development of moderate to severe anemia and to examine the relationship
between anemia and 90d mortality.
Results: A total of 8240 daily hemoglobin values were measured in 1893 subjects. Mean (SD) number of
hemoglobin values per patient was 4.4 (4.0). One in three subjects (33.9%) had at least mild anemia at
presentation, 3 in 5 (62.1%) were anemic at some point during their hospital stay, and 1 in 2 (54.5%) survivors were
discharged from the hospital anemic. Anemia increased with illness severity and was more common in those with
comorbid illnesses, female gender, and poor outcomes. Yet, even among men and in those with no comorbidity
or only mild illness, anemia during hospitalization was common (~55% of subjects). When anemia was moderate
to severe (≤ 10 g/dL), its development was independently associated with increased 90d mortality, even among
hospital survivors.
Conclusions: Anemia was common in hospitalized CAP and independently associated with 90d mortality when
hemoglobin values were 10 g/dL or less. Whether prevention or treatment of CAP-associated anemia would
improve clinical outcomes remains to be seen.
Background
T h ep r e v a l e n c eo fa n e m i ai nt h ei n t e n s i v ec a r eu n i t
(ICU) is well-described [1-4]. In this setting, anemia is
common, increasing during the hospital stay, and asso-
ciated with poor outcomes. Less is known, however, of
the prevalence of anemia in hospitalized patients with
lesser illness severity or without organ dysfunction [5,6].
There is increasing interest in manipulating hemoglobin
values in hospitalized patients with interventions such as
red blood cell transfusions [7], recombinant human ery-
thropoetin [8], and blood substitutes [9]. If these or
other as yet undiscovered therapies were proven to
improve patient outcomes, their application to clinical
practice would require a much better understanding of
anemia in both ICU and non-ICU patients.
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most frequent causes of hospitalization in the United
States (US), affecting both otherwise healthy patients
and those with comorbid illness. In patients hospitalized
with CAP, studies show that anemia is common and
associated with increased length of stay and mortality
[10-18]. Yet, most studies were small, retrospective, or
limited to a single center. Existing large studies primar-
ily examined hemoglobin values at presentation
[10,13,14] and therefore miss the evolution of changes
in hemoglobin values over the course of hospitalization.
Furthermore, no study has focused exclusively on ane-
mia in CAP, its course over time, and its prevalence
across important subgroups to understand the indepen-
dent contribution of illness severity, comorbidty, and
gender on the development of anemia.
We therefore examined the development and progres-
sion of anemia in a large, prospective, multicenter
inception cohort study of subjects presenting to the
emergency department with CAP, a primarily non-criti-
cally ill cohort with less than 1 in 6 subjects admitted to
an ICU. Our primary goals were to describe the preva-
lence of anemia at presentation and its development
over time, not only in those previously at risk of anemia,
but also in those without common anemia risk factors.
Furthermore, we sought to determine whether anemia is
independently associated with increased 90d mortality.
We hypothesized that anemia would increase with ill-
ness severity and be greater in those with comorbid ill-
nesses, female gender, and poor outcomes.
Methods
Sites and subjects
The Genetic and Inflammatory Markers of Sepsis (Gen-
IMS) study enrolled subjects at 28 academic and com-
munity hospitals in southwestern Pennsylvania,
Connecticut, southern Michigan, and western Tennessee
from December 2001 and November 2003. GenIMS
included patients ≥ 18 years old with a clinical and radi-
ologic diagnosis of pneumonia, as per the criteria of
Fine et al [13]. We excluded: transfer from another hos-
pital; discharge from a hospital within the prior 10 days;
an episode of pneumonia within the prior 30 days;
chronic mechanical ventilation, cystic fibrosis, or active
pulmonary tuberculosis; admission for palliative care;
previous enrollment in the study; incarceration; and
pregnancy. For the purposes of this GenIMS substudy,
we excluded subjects who had no hemoglobin measure-
ment during their hospital stay. Participants or their
proxies provided written consent. We obtained approval
from the Institutional Review Boards of the University
of Pittsburgh and all participating sites. Other results of
this study, not inclusive of these anemia data, have been
published elsewhere [19,20].
Clinical definitions and outcome variables
We prospectively collected detailed baseline and sequen-
tial clinical and laboratory information using structured
subject or proxy interviews, bedside assessments, and
medical record abstraction. We obtained all hemoglobin
values performed for clinical purposes from the medical
record. The World Health Organization defines anemia
as hemoglobin levels <13 g/dL in men or <12 g/dL in
women [21]. Because we wished to explore the preva-
lence and significance of anemia of varying degrees of
severity, we classified anemia based on hemoglobin
values into categories consisting of no anemia (>13 g/
dL), at least borderline (≤ 13 g/dL), at least mild (≤ 12
g/dL), at least moderate (≤ 10 g/dL), and severe (≤ 8g /
dL) anemia. The hemoglobin value obtained on day 1
was defined as the baseline “h e m o g l o b i no np r e s e n t a -
tion” value. The final hemoglobin measured in the hos-
pital was the discharge value.
We ascertained comorbid conditions using the Charl-
son comorbidity index [22] and severity of illness using
APACHE III [23] and the Pneumonia Severity Index
(PSI) [13]. We defined severe sepsis as pneumonia plus
acute organ dysfunction following the 2001 International
C o n s e n s u sC r i t e r i a[ 2 4 ] .W ed e f i n e da c u t eo r g a nd y s -
function as a new Sequential Organ Failure Assessment
(SOFA) [25] score of ≥ 3 in any of six organ systems,
based on the international Sepsis Occurrence in the
Acutely ill Patient study [26]. We determined survival
post-discharge by telephone and National Death Index
search. We used 90-day mortality as our primary mea-
sure of survival, based on endpoint recommendations
for sepsis trials from two recent international expert
panels [27,28].
Statistical analysis
Statistical analyses were performed using SAS software,
version 9.1 (SAS Institute, Cary, NC), with statistical sig-
nificance set at p < 0.05. We compared differences for
single points in time using chi-square test or Fisher’s
exact test for dichotomous data and Student’st - t e s to r
Mann-Whitney U for continuous data. For analyses in
which a baseline value was necessary (determining the
prevalence of anemia on presentation and stratifying the
subsequent course of hemoglobin values by presenting
hemoglobin category), we limited our analysis to those
subjects with day 1 hemoglobin values obtained (n =
1838). For analyses not requiring a baseline value (deter-
mining the prevalence of anemia during hospitalization,
risk factors for its development, and the association with
90d mortality), we included all subjects who had hemo-
globin measured at least once during their hospital stay
(the “inpatient CAP analysis cohort”, n = 1893).
To determine variables independently associated with
the development of moderate to severe anemia in
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able logistic regression using backward stepwise variable
selection with p < 0.05 for model retention. Variables
eligible for inclusion in the model were baseline charac-
teristics (age, gender, race, Charlson comorbidity,
chronic cardiac or respiratory disease, cirrhosis, and
chronic hemodialysis), day 1 severity of illness
(APACHE III, PSI, SOFA), and clinical course (develop-
ment of severe sepsis, ICU admission, and use of
mechanical ventilation). The same variables were used
for modeling 90d mortality, but also included the devel-
opment of moderate to severe anemia and whether a
subject received a blood transfusion during their hospi-
tal stay. For both models, we conducted our primary
analyses in the entire inpatient CAP analysis cohort,
with secondary analysis of the 90d mortality model lim-
ited to subjects who survived to hospital discharge.
Results
Study population and outcomes
Of 2320 enrolled subjects, we excluded 288 (12%) who
were discharged from the emergency department and
137 (6%) because their treating physicians subsequently
ruled out pneumonia as the cause of their illness. The
remaining 1895 subjects comprised the inpatient CAP
cohort (figure 1 and table 1). In this group, 1838
(97.0%) had hemoglobin values obtained on day 1 and
recorded in the medical record, while all but two had
hemoglobin values obtained at least once during their
stay, leaving 1893 (99.7%) in the analysis cohort. A total
of 8240 daily hemoglobin values were measured. Mean
(SD) number of hemoglobin values per patient was 4.4
(4.0), with median (interquartile range) 3 (2 to 5). Mean
(SD) hospital length of stay was 7.3 (5.0) days. After day
1, hemoglobin values were available for a mean (SD) of
55.3% (7.3%) subjects who remained hospitalized each
day. Of the 1893 in the analysis cohort, 114 (6.0%) had
positive sputum cultures, 139 (7.3) were bacteremic, 582
subjects (30.7%) developed severe sepsis, 124 (6.6%) died
within 30d of enrollment, and2 1 5( 1 1 . 4 % )d i e dw i t h i n
90d of enrollment.
Anemia at presentation
Among the 1838 subjects with day 1 measurements,
mean (SD) hemoglobin was 12.8 (1.9) g/dL. One in
three (33.9%) subjects had at least mild anemia (hemo-
globin ≤ 12 g/dL) at presentation (table 2). This was
true even in men, in those with no prior history of
chronic disease, and in those without acute organ dys-
function or requiring ICU care. More severe forms of
Figure 1 Flow diagram for the entire GenIMS cohort.
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at least moderate (≤ 10 g/dL) or severe (≤ 8 g/dL) ane-
mia at presentation. In general, each level of anemia at
presentation was significantly more common in women,
those with comorbidities, and the more severely ill.
Anemia over time
Three in five (62.1%) subjects developed at least mild
anemia at some point during their hospital stay (table
2), most of which occurred by the second hospital day.
Anemia was more common in women, those with
comorbidities, and the more severely ill, yet was often
present in those without these risk factors. For those
remaining in the hospital, anemia became progressively
more common with each passing day (figure 2). Over
time, hemoglobin values converged to around 10 g/dL,
regardless of the presenting hemoglobin value (figure 3).
Of all subjects, 176 (9.3%) received at least one blood
transfusion. Of those who were transfused, mean (SD)
pre-transfusion hemoglobin was 8.5 (1.2) g/dL.
Anemia at hospital discharge
Of the 1893 subjects in the analysis cohort, 1806 (95.4%)
survived to hospital discharge. Hemoglobin was mea-
sured on the day of discharge in 512 (28.3%) subjects
and within 48 hours before discharge in an additional
795 (44%) subjects. For a minority of subjects (n = 164,
9%), the last available hemoglobin concentration mea-
surement was more than 96 hours before discharge.
Mean (SD) discharge hemoglobin was 11.9 (1.8) g/dL
Table 1 Clinical characteristics at baseline and during the study
ICU Admission Severe Sepsis Comorbidity
All Yes No Yes No Yes No
N 1893 303 (16.0) 1590 (84.0) 582 (30.7) 1311 (69.3) 1373 (72.5) 520 (27.5)
Age, years, mean (SD) 67.8 (16.8) 68.1 (15.7) 67.7 (17.0) 71.5 (15.7) 66.1 (17.0) 69.9 (15.3) 62.2 (19.1)
Male gender, n (%) 983 (51.9) 168 (55.4) 815 (51.3) 329 (56.5) 654 (49.9) 738 (53.8) 245 (47.1)
Race, n (%)
White 1527 (80.7) 245 (80.9) 1282 (80.6) 494 (84.9) 1033 (78.8) 1121 (81.6) 406 (78.1)
Black 299 (15.8) 51 (16.8) 248 (15.6) 73 (12.5) 226 (17.2) 206 (15.0) 93 (17.9)
Other 67 (3.5) 7 (2.3) 60 (3.8) 15 (2.6) 52 (4.0) 46 (3.4) 21 (4.0)
Underlying disease
a
Charlson comorbidity >0, n (%) 1373 (72.5) 225 (74.3) 1148 (72.2) 446 (76.6) 927 (70.7) 1373 (100.0) n/a
Charlson comorbidity, mean (SD) 1.9 (2.2) 1.9 (2.2) 1.9 (2.2) 2.2 (2.3) 1.8 (2.2) 2.7 (2.2) n/a
Cardiovascular disease, n (%) 487 (25.7) 79 (26.1) 408 (25.7) 163 (28.0) 324 (24.7) 487 (35.5) n/a
Respiratory disease, n (%) 717 (37.9) 118 (38.9) 599 (37.7) 207 (35.6) 510 (38.9) 717 (52.2) n/a
Chronic hemodialysis, n (%) 48 (2.5) 11 (3.6) 37 (2.3) 9 (1.5) 39 (3.0) 48 (3.5) n/a
Cirrhosis, n (%) 5 (0.3) 1 (0.3) 4 (0.3) 1 (0.2) 4 (0.3) 5 (0.4) n/a
PSI, mean (SD) 99.8 (38.1) 124.2 (40.7) 95.1 (35.8) 121.2 (40.4) 90.3 (32.9) 106.8 (37.8) 81.4 (32.3)
PSI class, n (%)
I and II 428 (22.6) 26 (8.6) 402 (25.3) 55 (9.5) 373 (28.5) 216 (15.7) 212 (40.8)
III 392 (20.7) 35 (11.6) 357 (22.5) 76 (13.1) 316 (24.1) 265 (19.3) 127 (24.4)
IV 708 (37.4) 116 (38.3) 592 (37.2) 230 (39.5) 478 (36.5) 571 (41.6) 137 (26.3)
V 365 (19.3) 126 (41.6) 239 (15.0) 221 (38.0) 144 (11.0) 321 (23.4) 44 (8.5)
APACHE III, mean (SD) 56.1 (17.9) 67.7 (20.5) 53.9 (16.4) 65.8 (19.8) 51.8 (15.1) 58.6 (17.6) 49.4 (16.8)
SOFA, mean (SD) 2.4 (1.9) 3.7 (2.7) 2.2 (1.7) 3.7 (2.4) 1.8 (1.3) 2.5 (2.1) 2.1 (1.6)
Duration of symptoms prior to ED
presentation, days
b, mean (SD)
4.9 (7.1) 4.7 (6.8) 5.0 (7.2) 4.9 (7.6) 5.0 (6.9) 4.8 (7.2) 5.3 (7.0)
Antibiotics before presentation, n (%) 333 (17.6) 57 (18.8) 276 (17.4) 93 (16.0) 240 (18.3) 233 (17.0) 100 (19.2)
Transfusion in hospital, n (%) 176 (9.3) 97 (32.0) 79 (5.0) 125 (21.5) 51 (3.9) 138 (10.1) 38 (7.3)
ICU admission, n (%) 303 (16.0) 303 (100.0) n/a 225 (38.7) 78 (5.9) 225 (16.4) 78 (15.0)
Mechanical ventilation, n (%) 132 (7.0) 123 (40.6) 9 (0.6) 132 (22.7) 0 (0.0) 89 (6.5) 43 (8.3)
Hospital length of stay, days, mean (SD) 7.3 (5.0) 12.7 (7.2) 6.3 (3.6) 10.3 (6.7) 6.0 (3.3) 7.5 (4.9) 7.0 (5.3)
Hospital mortality, n (%) 87 (4.6) 53 (17.5) 34 (2.1) 83 (14.3) 4 (0.3) 71 (5.2) 16 (3.1)
90-day mortality, n (%) 215 (11.4) 80 (26.4) 135 (8.5) 150 (25.8) 65 (5.0) 184 (13.4) 31 (6.0)
PSI, Pneumonia Severity Index; SOFA, Sequential Organ Failure Assessment; APACHE III, Acute Physiology and Chronic Health Evaluation III score; ED, Emergency
Department; ICU, intensive care unit.
aAccording to the method of Charlson et al [22]
b Missing for 19 subjects
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mild anemia at discharge. More than half (54.4%) of survi-
vors were sent home with at least mild anemia (table 2),
including 63% of women and 46% of men. Of hospital sur-
vivors with at least two measurements during their stay,
hemoglobin dropped a mean (SD) of 1.1 (1.3) g/dL.
Variables independently associated with development of
moderate to severe anemia
In multivariable modeling, we explored risk factors for
the development of moderate to severe anemia (hemo-
globin ≤ 10 g/dL) (table 3). Female gender, comorbidity,
initial illness severity, and measures of clinical course
were independently associated with moderate to severe
anemia. White race and the presence of chronic respira-
tory disease were inversely associated with moderate to
severe anemia. These latter two observations did not
appear to be due differences in the incidence or number
of units of blood transfused, neither of which were
greater in these groups (data not shown).
Anemia and its association with 90d mortality
After adjusting for baseline characteristics, initial illness
severity, and measures of clinical course, the development
of moderate to severe anemia (hemoglobin ≤ 10 g/dL) at
any time during the hospital stay was independently asso-
ciated with increased 90d mortality (adjusted odds ratio
[95% confidence interval]: 1.59 [1.12 to 2.25], p = 0.01)
(table 4). This association persisted when limiting our ana-
lysis to subjects who survived to hospital discharge (1.64
[1.09 to 2.47], p = 0.02) (table 5). In neither model was
occurrence of no more than mild anemia or the receipt of
a blood transfusion independently associated with mortal-
ity. The latter was true even if moderate to severe anemia
was excluded from the model (data not shown).
Discussion
Anemia was surprisingly common in hospitalized CAP,
increasing with illness severity and greater in those
with comorbid illnesses, female gender, and poor out-
comes. Yet, even among men and in those with no
comorbidity or only mild illness, anemia was extremely
common. One in three subjects had at least mild ane-
mia at presentation, 3 in 5 were anemic at some point
during their hospital stay, and 1 in 2 were sent home
anemic. When anemia was moderate to severe (hemo-
globin ≤ 10 g/dL), its development was independently
associated with increased 90d mortality, even among
hospital survivors and after accounting for illness
severity.
Table 2 Hemoglobin on day 1, during hospitalization, and at discharge in the GenIMS cohort.
ICU Admission Severe Sepsis Comorbidity Gender
All Yes No Yes No Yes No Female Male
Hemoglobin on day 1
a, n (%)
No anemia (hgb >13 g/dL) 857 (46.6) 132 (44.4) 725 (47.0) 234 (41.5) 623 (48.9)* 593 (44.5) 264 (52.2)* 331 (37.5) 526 (55.0)*
At least borderline (hgb ≤ 13 g/dL) 981 (53.4) 165 (55.6) 816 (53.0) 330 (58.5) 651 (51.1)* 739 (55.5) 242 (47.8)* 551 (62.5) 430 (45.0)*
At least mild (hgb ≤ 12 g/dL) 624 (33.9) 115 (38.7) 509 (33.0) 232 (41.1) 392 (30.8)* 481 (36.1) 143 (28.3)* 353 (39.9) 272 (28.5)*
At least moderate
(hgb ≤ 10 g/dL)
149 (8.1) 43 (14.5) 106 (6.9)* 74 (13.1) 75 (5.9)* 126 (9.5) 23 (4.5)* 82 (9.3) 67 (7.0)
Severe (hgb ≤ 8 g/dL) 20 (1.1) 9 (3.0) 11 (0.7)* 10 (1.8) 10 (0.8) 17 (1.3) 3 (0.6) 17 (1.9) 3 (0.3)*
Hemoglobin during hospital stay
b, n (%)
No anemia (hgb >13 g/dL) 407 (21.5) 36 (11.9) 371 (23.3)* 89 (15.3) 318 (24.3)* 280 (20.4) 127 (24.4) 133 (14.6) 274 (27.9)*
At least borderline (hgb ≤ 13) g/dL 1486 (78.5) 267 (88.1) 1219 (76.7)* 493 (84.7) 993 (75.7)* 1093 (79.6) 393 (75.6) 777 (85.4) 709 (72.1)*
At least mild (hgb ≤ 12 g/dL) 1175 (62.1) 244 (80.5) 931 (58.6)* 430 (73.9) 745 (56.8)* 879 (64.0) 296 (56.9)* 639 (70.2) 536 (54.5)*
At least moderate
(hgb ≤ 10 g/dL)
511 (27.0) 170 (56.1) 341 (21.4)* 259 (44.5) 252 (19.2)* 388 (28.3) 123 (23.7)* 275 (30.2) 236 (24.0)*
Severe (hgb ≤ 8 g/dL) 93 (4.9) 50 (16.5) 43 (2.7)* 59 (10.1) 34 (2.6)* 67 (4.9) 26 (5.0) 53 (5.8) 40 (4.1)
Hemoglobin at discharge in survivors
c, n (%)
No anemia (hgb >13 g/dL) 473 (26.2) 44 (17.6) 429 (27.6)* 100 (20.0) 373 (28.5)* 324 (24.9) 149 (29.6)* 161 (18.4) 312 (33.4)*
At least borderline (hgb ≤ 13) g/dL 1333 (73.8) 206 (82.4) 1127 (72.4)* 399 (80.0) 934 (71.5)* 978 (75.1) 355 (70.4)* 712 (81.6) 621 (66.6)*
At least mild (hgb ≤ 12 g/dL) 982 (54.4) 171 (68.4) 811 (52.1)* 322 (64.5) 660 (50.5)* 729 (56.0) 253 (50.2)* 552 (63.2) 430 (46.1)*
At least moderate (hgb ≤ 10 g/dL) 286 (15.8) 56 (22.4) 230 (14.8)* 113 (22.6) 173 (13.2)* 213 (16.4) 73 (14.5) 164 (18.8) 122 (13.1)*
Severe (hgb ≤ 8 g/dL) 16 (0.9) 3 (1.2) 13 (0.8) 5 (1.0) 11 (0.8) 10 (0.8) 6 (1.2) 12 (1.4) 4 (0.4)*
Hgb, hemoglobin; ICU, intensive care unit
* p < 0.05 for within group comparison
a N = 1838 had day 1 hemoglobin measured
b N = 1893 had hemoglobin values obtained at least once during their stay
c N = 1806 hospital survivors
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depends upon the definition used. The World Health
Organization defines anemia as hemoglobin levels <13
g/dL in men or <12 g/dL in women [21]. According to
these criteria, anemia is prevalent in 2.9% of men and
7.5% of women in the general US population [29], rising
to around 7-9% in the elderly [29,30]. Using a conserva-
tive cutoff of 12 g/dL for both genders, the prevalence
of anemia seen in our study was considerably higher
than that of the general population. Given the known
associations of WHO-defined anemia with increased
mortality [31], as well as poor physical and cognitive
function [32], our findings offer cause for concern.
Previous large inpatient CAP cohort studies defined
anemia as a hemoglobin of <10 g/dL or hematocrit
<30%, yielding a prevalence of anemia on presentation
of 7-12% [10,13,14], proportions which are consistent
with our own. Our study is unique, in that we were able
to describe not only the prevalence of anemia on pre-
sentation, but its development over time and its persis-
tence at the time of hospital discharge. Furthermore,
rather than focusing on arbitrary cutoffs, we explored
the full spectrum of anemia severity across important
subgroups, and in doing so, can better understand the
prevalence and significance of anemia in hospitalized
CAP and the independent contribution of patient and
illness characteristics to its development.
Why was anemia so common in hospitalized CAP, even
among those without obvious risk factors? The day 1 pre-
valence speaks to the significant systemic derangement
that likely has already occurred in CAP patients at the
time of presentation, long before repeated blood draws
Figure 2 Prevalence of anemia by day for patients remaining in hospital on each day and having a hemoglobin obtained that day.
ICU patients refers to those who spent at least one day in the ICU. Non-ICU patients were never admitted to the ICU. During the first week, the
majority of hemoglobin values were obtained from non-ICU patients. After day 7, those still remaining in the hospital and providing daily
hemoglobin values were more likely to have spent at least one day of their hospital stay in the ICU. Despite this, 2/3 (341 of 511) of those with
moderate to severe anemia were non-ICU patients.
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explain low hemoglobin levels. The precipitous decline in
hemoglobin values that occurred over the first few days
of hospitalization is consistent with that seen in the ICU,
where hemoglobin values may decline by >0.5 g/dL/day
in non-bleeding patients [33,34]. These changes are
believed to be due not only to dilutional effects of fluids
and frequent blood draws [6], but also to other sources
of blood loss (gastric stress bleeding, surgical proce-
dures), effects of inflammatory cytokines, inadequate red
cell production, and excessive red cell destruction [35].
Unfortunately, the nature of the data collected in our
study precluded us from identifying which of these fac-
tors were at work in any given patient. Certain infections,
such as Mycoplasma pneumonia, are associated with ane-
mia. Very few subjects in our study had positive blood or
sputum cultures and cultures were not universally drawn,
which is typical for observational studies of CAP [14,36].
Consequently, we could not reliably determine whether
t h ep r e v a l e n c eo rs e v e r i t yo fa n e m i av a r i e db yp r e s e n c e
of bacteremia or by type of infecting organism.
In our study, the presence of moderate to severe anemia
was independently associated with increased 90d mortality
after accounting for factors such as comorbidity, initial
illness severity, the development of severe sepsis, and use
of mechanical ventilation. This association persisted when
limited to hospital survivors. Other studies of CAP
patients have identified anemia as a risk factor for mortal-
ity [11,15,17,18] and an initial hematocrit level of <30% is
a component of the Pneumonia Severity Index [13], which
classifies 30d mortality risk. Yet, does the anemia actually
cause increased mortality or is it merely an additional
marker of illness severity, and therefore, mortality?
In chronic disease states, inflammatory cytokines are
thought to contribute to the development of anemia by
shortening red blood cell survival and impairing ability
of red blood cell progenitors to respond to erythropoie-
tin [37]. Despite clinical recovery, many patients with
CAP leave the hospital with ongoing subclinical inflam-
mation, which is associated with an increased risk of
death due to cardiovascular disease, cancer, infections,
and renal failure [38]. If a proinflammatory state is asso-
ciated with both the development of anemia and mortal-
ity, might anemia be in the causal pathway between
inflammation and mortality? Observational studies like
our own cannot answer this question, yet interventional
studies suggest that while anemia is bad, correcting it
not necessarily helpful and perhaps, deleterious [3,8].
Figure 3 Course of hemoglobin by presenting hemoglobin category for patients remaining in hospital and having a hemoglobin
obtained that day. Regardless of presenting hemoglobin category, mean hemoglobin concentrations regressed to a common value of around
10 g/dl. Censored for <5 observations/category/day to reduce effect of outliers. N = 55 subjects with no day 1 hemoglobin measurement
excluded.
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work that deserve consideration. We did not have access
to pre-CAP hemoglobin levels, and were therefore
unable to determine if anemia preceded the develop-
ment of pneumonia. Yet anemia was common even
among those without well-known risk factors for
chronic anemia. Hemoglobin values were only available
if drawn for clinical purposes, which occurred in 97% of
subjects on day 1, but in slightly more than half of
those remaining in the hospital on each subsequent day.
Consequently, though our anemia prevalence rates for
day 1 and the entire hospital stay are accurate; our day-
specific rates (figure 2) may be either over or underesti-
mated depending on hemoglobin values for those who
were not sampled that day. T h ep r e v a l e n c eo fa n e m i a
among inpatients increased over the hospital stay in
part due to discharge of less severely ill patients, with
the remaining patients subject to the hemoglobin lower-
ing effects of additional blood draws. Even so, the preva-
lence of anemia in those who were discharged was quite
Figure 4 Discharge hemoglobin values among hospital survivors. For this graph, we analyzed the last hemoglobin measurement in subjects
discharged alive from the hospital (n = 1806). Hemoglobin was measured on the day of discharge in 512 (28.3%) subjects and within 48 hours
before discharge in an additional 795 (44%) subjects. For a minority of subjects (n = 164, 9%), the last available hemoglobin concentration
measurement was more than 96 hours before discharge. Mean (SD) discharge hemoglobin was 11.9 (1.8) g/dL, indicating that the average
hospital survivor had mild anemia at discharge.
Table 3 Variables independently associated with
development of moderate to severe anemia.
Variable Adj OR 95% CI P-value
Age 0.99 0.979 0.998 0.022
Male 0.46 0.36 0.59 <0.001
Race 0.001
White ref
Black 1.86 1.33 2.60
Other 1.43 0.76 2.69
Charlson comorbidity 1.10 1.04 1.16 0.001
Chronic respiratory disease 0.46 0.35 0.59 <0.001
APACHE III 1.02 1.01 1.03 <0.001
PSI 1.01 1.01 1.02 <0.001
Severe sepsis 1.40 1.06 1.85 0.017
ICU admission 1.79 1.25 2.55 0.001
Mechanical ventilation 3.57 2.07 6.15 <0.001
Constant 0.14 <0.001
ICU, intensive care unit; Adj OR, adjusted odds ratio; CI, confidence interval;
APACHE III, Acute Physiology and Chronic Health Evaluation III score; PSI,
Pneumonia Severity Index.
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Page 8 of 10high. We are unable to explain why chronic respiratory
disease appeared protective for the development of ane-
mia in our models when it is known to be a risk factor
for anemia in the outpatient setting [37]. Importantly,
this observation did not seem to be due differential
transfusion rates in our cohort. It was impractical to
draw blood samples after hospital discharge; therefore
our results only describe hemoglobin changes during
the hospital stay. Whether anemia persists after hospital
discharge remains to be seen. If so, this might present a
unique time to intervene if persistent abnormalities
were also associated with adverse outcomes [39].
Conclusions
Anemia was common in hospitalized CAP, not only in
those with severe illness or anemia risk factors, but also
in those with mild illness and no risk factors. When
moderate to severe (hemoglobin ≤ 10 g/dL), the devel-
opment of anemia was independently associated with
increased 90d mortality. Wheth e rp r e v e n t i o no rt r e a t -
ment of CAP-associated anemia would improve clinical
outcomes remains to be seen.
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